Unique structural features of firmonertinib enhance binding and activity against EGFR mutant proteins including ex20ins mutant proteins in cell ...
Everyone’s favorite bracket challenge has returned. That’s right—it’s time once again for Fierce Pharma Marketing’s annual ...
Topline global pivotal Phase 3 data for firmonertinib in first-line EGFR exon 20 insertion mutant NSCLC expected mid-2026Global pivotal Phase 3 ...
Furmonertinib, a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, has demonstrated systemic and central nervous system (CNS) antitumor activity in patients with EGFR ...
Subcutaneous (SC) amivantamab reduces administration from hours to minutes, with efficacy and safety consistent with intravenous (IV) amivantamab1,2,3,4,5 SC amivantamab is now authorised across all ...
Adult patients on biweekly IV amivantamab or SC Rybrevant Faspro may now transition to a monthly subcutaneous schedule starting on or after week 5. The Food and Drug Administration (FDA) has approved ...
What Is It, and Why Does It Matter? Rybrevant Faspro is an under-the-skin (subcutaneous, or SC) injection form of the anticancer medicine Rybrevant (amivantamab). The FDA has approved a new monthly ...
Builds on RYBREVANT FASPRO™ FDA approval to deliver the simplest and fastest combination regimen for EGFR+ non-small cell lung cancer1,3-6 HORSHAM, Pa., Feb. 17, 2026 /PRNewswire/ -- Johnson & Johnson ...
The development of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) dramatically altered the treatment for non-small cell lung cancer (NSCLC). The implementation of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results